Tag: cancer
Cancer, CVD Patients More Likely to Contract COVID-19
Patients with cancer and cardiovascular disease may have a potentially higher risk of contracting COVID-19 and a higher likelihood of experiencing adverse outcomes from the disease, according to a paper published March 20... read more
A Team Response to a Potential Killer: Sepsis
Our bodies are very good at fighting infection. The immune system reacts and attacks bacteria and viruses that make us sick. But sometimes the immune reaction is so strong that it damages the body. This is called a septic... read more
Early Norepinephrine Has Potential for Septic Shock
Standard sepsis algorithms have suggested completing a fluid bolus before starting vasopressors in patients with septic shock, but multiple observational trials have shown an association between early vasopressor use and... read more
TCR Activation Mimics CD127 low PD-1 high Phenotype and Functional Alterations of T Lymphocytes from Septic Shock Patients
The proportion of CD127lowPD-1high T cells in patients was increased compared with healthy volunteers, although no global CD127 regulation was observed. Our results suggest that TCR activation participates in the occurrence... read more
Many Doctors Have Distorted Perceptions of the Value of Medical Tests
In 2014, the Canadian Task Force on Preventive Health Care recommended against the prostate-specific antigen (PSA) test used to screen for prostate cancer in healthy men, concluding that it results in substantial harms via... read more
Clinical Performance of Beta-D-Glucan for the Diagnosis of Pneumocystis Pneumonia in Cancer Patients Tested with PCP PCR
Patients negative by both Beta-D glucan (BDG) and PCR were unlikely to have Pneumocystis pneumonia (PCP). In patients with a compatible clinical syndrome for PCP, higher BDG values (>200 pg/mL) were consistently associated... read more
Gene-silencing Technology Gets First Frug Approval After 20-year Wait
US regulators have approved the first therapy based on RNA interference (RNAi), a technique that can be used to silence specific genes linked to disease. The drug, "patisiran", targets a rare condition that can impair heart... read more
AKI and Electrolyte Disorders in the Critically Ill Patient with Cancer
This review outlines key knowledge areas for critical care physicians and nephrologists caring for patients with cancer and associated kidney issues such as acute kidney injury (AKI) and electrolyte disorders. Specifically,... read more
Lack of association between airflow limitation and recurrence of venous thromboembolism among cancer patients with pulmonary embolism
The presence of airflow limitation did not increase the risk of VTE recurrence in cancer patients with PE. Prospective studies are needed to validate this finding. Among 401 cancer patients with newly diagnosed PE, spirometry-based... read more
Precision Medicine, Genome Sequencing, and Improved Population Health
Despite controversy, major health systems across the globe are obtaining and making use of genome sequence data in patients they care for, hoping this approach will prove beneficial.1 Genome sequencing technology, a key driver... read more
The Gene: An Intimate History
A fascinating and often sobering history of how humans came to understand the roles of genes in making us who we are. From the Pulitzer Prize-winning author of The Emperor of All Maladies, a fascinating history of the gene... read more
Meta-Analysis Shows Mixed Results with Palliative Care
Palliative care was tied to some improvements in quality of life (QOL) in critically ill patients, but the impact on caregiver outcomes was mixed, and there was no significant association between palliative care delivery... read more
Endobronchial Ultrasound Can ID Pulmonary Thromboembolism
The researchers found that in four cases (0.7 percent), filling defects were demonstrated in central pulmonary arteries while sampling mediastinal lymph nodes.... read more
FDA Approves ‘living drug’ to Cure Cancer
FDA has approved the first treatment to redesign immune system so it attacks the cancer cells. Kymriah therapy, which leaves 83% of people free of a type of blood cancer, costs about $475,000 and was developed by Novartis.... read more
